Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of repeat doses of
T-cell immunotherapy (SB-728mR-T) following cyclophosphamide conditioning.
CCR5 is a major co-receptor for HIV entry into T-cells. Disruption of CCR5 by zinc finger
nuclease (SB-728mR), blocks HIV entry into the T-cells, therefore, protects the T-cells from
HIV infection. Safety (primary outcome) and anti-viral effect (secondary outcome) of zinc
finger nuclease-mediated CCR5 disrupted autologous T-cells (SB-728mR-T) will be evaluated in
the study.